[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634294":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":26,"collaborators":25,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":25,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":25,"enrollmentInfo":37,"targetDuration":25,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":25,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":25},{"fullName":5,"class":6},"Mackay Memorial Hospital","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"AB sequence: Vadadustat add-on followed by darbepoetin alfa alone","Participants receive oral vadadustat in addition to background darbepoetin alfa during period 1 for 8 weeks, followed by background darbepoetin alfa alone during period 2 for 8 weeks. The two treatment periods are separated by a 4-week washout period.",[12],"Drug: Vadadustat",{"label":14,"type":6,"description":15,"interventionNames":16},"BA sequence: Darbepoetin alfa alone followed by vadadustat add-on","Participants receive background darbepoetin alfa alone during period 1 for 8 weeks, followed by oral vadadustat in addition to background darbepoetin alfa during period 2 for 8 weeks. The two treatment periods are separated by a 4-week washout period.",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Vadadustat","Vadadustat administered orally for 8 weeks during the assigned treatment period. In this two-period crossover study, the two treatment periods are separated by a 4-week washout period.",[9,14],[24],"Darbepoetin alfa",null,{"type":27,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100634294","phase-4-effects-of-vadadustat-on-anemia-quality-of-life-and-inflammation-in-dialysis-patients-100634294",false,"NCT07537816","Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients","A Prospective Interventional Study Evaluating the Effects of Vadadustat on Anemia, Quality of Life, and Inflammatory Response in Dialysis Patients and Exploring Predictors of Treatment Response","Inclusion Criteria:\n\n* Age 18 years or older\n* Receiving maintenance peritoneal dialysis\n* Followed at the outpatient clinics of MacKay Memorial Hospital\n* Receiving background darbepoetin alfa therapy\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Blood pressure \\>170\u002F80 mmHg on three separate occasions\n* Recent cardiovascular events within the past 3 months, including coronary artery disease, myocardial ischemia, cerebrovascular disease, or peripheral artery disease\n* Gastrointestinal bleeding within the past 3 months\n* Active malignancy","ALL","18 Years",{"count":38,"type":39},40,"ESTIMATED","INTERVENTIONAL",[42],"PHASE4","This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflammation, and dialysis adequacy.",[45],"Renal Anemia","NOT_YET_RECRUITING","2026-04-19",{"date":49,"type":50},"2026-04-23","ACTUAL",{"date":52,"type":39},"2026-04-15",{"date":54,"type":39},"2026-10-15",{"name":5,"class":6}]